Ustekinumab With Semi-EN vs Exclusive EN for Preoperative Crohn's Disease Optimization.

Abroad (travel likely)Recruiting

Conditions

Crohn Disease (CD)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Contact: Study coordinator (Xiang Gao) · gxiang@mail.sysu.edu.cn · +86-020-38663423

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Cranberry and Gut Health in Crohn's Disease

Crohn Disease (CD) · Crohn Disease

Abroad (travel likely)RecruitingEARLY_PHASE1

Worcester, United States

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

Inflammatory Bowel Disease (IBD) · Crohn Disease (CD) · Ulcerative Colitis (UC)

Abroad (travel likely)Recruiting

Calgary, Canada · Fredericton, Canada

Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease

Inflamatory Bowel Disease · Crohn Disease (CD)

Abroad (travel likely)Recruiting

Shanghai, China

IBD Biomarker Discovery and Validation Platform

Crohn Disease (CD) · Ulcerative Colitis (UC) · Inflammatory Bowel Diseases (IBD)

Abroad (travel likely)Recruiting

Guangzhou, China · Guangzhou, China